Statistics for Janux Therapeutics, (id:6517 JANX)

Valuation metrics

Market cap

2.64B

Enterprise value

1.81B

Trailing P/E (ttm)

-38.11

Forward P/E

-31.44

PEG ratio

-31.44

Price/Sales (ttm)

202.34

Price/Book (mrq)

4.01

Enterprise Value/Revenue

138.38

Enterprise Value/EBITDA

-21.53

Overview

Shares outstanding

52.48M

Float

38.00M

Shares short

4.31M

% Held by insiders

0.08%

% Held by institutions

0.95%

Average volume (10 days)

617.34K

Average volume (90 days)

Price summary

52-Week low

7.79

52-Week high

65.60

52-Week change

81.65%

Beta

3.52

50-Day moving average

50.06

200-Day moving average

43.70

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-8,164.46%

Operational effectiveness

Return on assets

-9.93%

Return on equity

-12.05%

Income statement

Revenue (ttm)

0.26

Revenue per share (ttm)

0.26

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-83,883,000.00

Net income to common (ttm)

-60,536,000.00

Diluted EPS (ttm)

-1.17

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

658.03M

Total cash per share (mrq)

12.54

Total debt (mrq)

23.43M

Total Debt/Equity (mrq)

3.57

Current ratio (mrq)

3.88K%

Book value per share (mrq)

12.54

Cash flow

Cash flow statement

-36,990,000.00

Levered free cash flow (LFCF)

-21,559,250.00